6533b824fe1ef96bd12809d4

RESEARCH PRODUCT

Rasburicase-induced Methemoglobinemia: A Case Report and Literature Review.

Francesca CacciatorePaolo D'angeloAntonino GiambonaAngela GuarinaClara MosaPiero FarruggiaIlaria PirroneSimona ScalzoAnna Paola Marcello

subject

Hemolytic anemiaMalemedicine.medical_specialtyAnemia HemolyticAdolescentUrate Oxidasemedicine.medical_treatmentMethemoglobinemiaPrecursor T-Cell Lymphoblastic Leukemia-LymphomaGastroenterologyLow oxygen saturationhemic and lymphatic diseasesInternal medicinemedicineRasburicaseHumansChemotherapybusiness.industryHematologymedicine.diseaseHemolysisRecombinant ProteinsTumor lysis syndromeOncologySupportive psychotherapyPediatrics Perinatology and Child HealthbusinessMethemoglobinemiamedicine.drug

description

Rasburicase is a recombinant urate oxidase enzyme indicated for tumor lysis syndrome, a potential life-threatening oncologic emergency that occurs most commonly during initial chemotherapy for hematological malignancies. As a result of the defects in the physiological antioxidant pathway, erythrocytes of patients with glucose-6-phosphate dehydrogenase deficiency are not protected against the oxidizing stress exerted by hydrogen peroxide generated with the administration of rasburicase. The authors report a 14-year-old patient, diagnosed with T-cell acute lymphoblastic leukemia, who developed methemoglobinemia and hemolytic anemia with low oxygen saturation after starting steroids, hyperhydratation, and rasburicase administration. The complications resolved with supportive therapy only.

yearjournalcountryeditionlanguage
2020-04-11Journal of pediatric hematology/oncology
10.1097/mph.0000000000001979https://pubmed.ncbi.nlm.nih.gov/33122582